My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Maruti Suzuki India firms up after good production in May
Jun 07,2017

The announcement was made during trading hours today, 7 June 2017.

Meanwhile, the S&P BSE Sensex was up 122.21 points, or 0.39% to 31,312.77.

On the BSE, 18,000 shares were traded in the counter so far, compared with average daily volumes of 65,625 shares in the past one quarter. The stock had hit a high of Rs 7,202.95 and a low of Rs 7,109.30 so far during the day. The stock hit a record high of Rs 7,249.30 on 1 June 2017. The stock hit a 52-week low of Rs 3,868.10 on 24 June 2016.

The stock had outperformed the market over the past one month till 6 June 2017, rising 7.34% compared with 4.23% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 21.37% as against Sensexs 7.92% rise. The scrip had also outperformed the market in past one year, rising 71.77% as against Sensexs 15.48% rise.

The large-cap company has equity capital of Rs 151.04 crore. Face value per share is Rs 5.

Maruti Suzuki Indias total sales rose 11.3% to 1.36 lakh units in May 2017 over May 2016. Domestic sales grew by 15.5% to 1.30 lakh units in May 2017 over May 2016. Export sales declined 36.3% to 6,286 units in May 2017 over May 2016.

Marutis net profit rose 15.8% to Rs 1709 crore on 20.3% growth in net sales to Rs 18005.20 crore in Q4 March 2017 over Q4 March 2016.

Maruti Suzuki India is Indias biggest car maker in terms of market share. Japanese parent Suzuki Motor Corporation currently holds 56.21% stake in Maruti Suzuki India (as per the shareholding pattern as on 31 March 2017).

Powered by Capital Market - Live News

Aegis Logistics drops after offloading stake in step-down subsidiary
Jun 07,2017

The announcement was made after market hours yesterday, 6 June 2017.

Meanwhile, the S&P BSE Sensex was up 129.40 points or 0.41% at 31,319.96. The S&P BSE Mid-Cap index was up 68.90 points, or 0.47% at 14,801.29.

On BSE, so far 15,000 shares were traded in the counter as against average daily volume of 1.02 lakh shares in the past one quarter. The stock hit a high of Rs 210 and a low of Rs 206.10 so far during the day. The stock had hit a record high of Rs 219.50 on 1 June 2017. The stock had hit a 52-week low of Rs 112.10 on 17 August 2016.

The stock had outperformed the market over the past one month till 6 June 2017, rising 7.96% compared with the Sensexs 4.46% rise. The scrip, however, underperformed the market over the past one quarter, advancing 3.4% as against the Sensexs 7.38% rise. The scrip, however, outperformed the market over the past one year, surging 73.05% as against the Sensexs 16.48% rise.

The small-cap company has equity capital of Rs 33.40 crore. Face value per share is Re 1.

Aegis Logistics said that the company has entered into a share subscription agreement with its subsidiary Aegis Gas (LPG) (AGPL) and AGPLs subsidiary Hindustan Aegis LPG (HALPG), and Itochu Petroleum Co., (Singapore) Pte. (Itochu), with respect to the subscription by Itochu to equity shares of HALPG representing 19.7% of the paid-up share capital of HALPG.

The company does not directly hold any shares in HALPG, Aegis Logistics said. However, AGPL is a wholly owned subsidiary of the company, and HALPG is a wholly owned subsidiary of AGPL, it said. Therefore, HALPG is a step-down subsidiary of the company, it added.

Aegis Logistics consolidated net profit fell 5.61% to Rs 29.77 crore on 190.13% surge in net sales to Rs 1267.78 crore in Q4 March 2017 over Q4 March 2016.

Aegis Logistics is Indias leading oil, gas, and chemical logistics company. The company has five distinct but related business segments, and operates a network of bulk liquid terminals, liquefied petroleum gas (LPG) terminals, filling plants, pipelines, and gas stations to deliver products and services.

Powered by Capital Market - Live News

Cadila Healthcare hits record high after USFDA nod for Mesalamine
Jun 07,2017

The announcement was made before trading hours today, 7 June 2017.

Meanwhile, the S&P BSE Sensex was up 131.62 points, or 0.42% to 31,322.18.

On the BSE, 8.97 lakh shares were traded in the counter so far, compared with average daily volumes of 1.24 lakh shares in the past one quarter. The stock had hit a high of Rs 539.40 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 491.05 so far during the day. The stock hit a 52-week low of Rs 305.05 on 24 June 2016.

The stock had outperformed the market over the past one month till 6 June 2017, 5.13% compared with 4.23% rise in the Sensex. The scrip had also outperformed the market in past one quarter, 10.80% as against Sensexs 7.92% rise. The scrip had also outperformed the market in past one year, 53.49% as against Sensexs 15.48% rise.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare informed that the US Food and Drug Administration (USFDA) has given final approval to market Mesalamine delayed-release tablets USP, I.2 g in the US market. Cadila Healthcare was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda (mesalamine).

Lialda is indicated for the treatment of mild to moderate ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease that affects approximately 700,000 people in the United States. The generic version of Lialda (mesalamine) will be produced at Moraiya plant in Ahmedabad. The estimated brand sales for Mesalamine delayed-release tablets USP, 1.2 g is $1.145 billion as per IMS MAT April 2017.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in the financial year ended March 2004.

Cadila Healthcares consolidated net profit fell 32.2% to Rs 385.5 crore on 6.5% rise in net sales to Rs 2417.50 crore in Q4 March 2017 over Q4 March 2016.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Vivimed Labs spurts after unit successfully completes USFDA inspection
Jun 07,2017

The announcement was made after market hours yesterday, 6 June 2017.

Meanwhile, the S&P BSE Sensex was up 129.40 points, or 0.41% at 31,319.96. The S&P BSE Small-Cap index was up 133.81 points, or 0.87% at 15,444.34.

On the BSE, 3.49 lakh shares were traded on the counter so far as against the average daily volume of 2.81 lakh shares in the past one quarter. The stock had hit a high of Rs 113.90 and a low of Rs 109.25 so far during the day. The stock had hit a record high of Rs 136.40 on 20 April 2017 and hit a 52-week low of Rs 68 on 9 August 2016.

The stock had underperformed the market over the past one month till 6 June 2017, declining 3.67% compared with the Sensexs 4.46% rise. The scrip had also underperformed the market over the past one quarter advancing 2.59% as against the Sensexs 7.38% rise. The scrip had, however, outperformed the market over the past one year advancing 32.97% as against the Sensexs 16.48% rise.

The small-cap company has equity capital of Rs 16.40 crore. Face value per share is Rs 2.

Vivimed Labs said that the companys API manufacturing facility located in Sant Celoni, Spain was recently inspected by the US Food and Drug Administration (USFDA) issued report with zero 483 observations.

Vivimed Labs consolidated net profit spurted 810% to Rs 114.75 crore on 25.8% increase in net sales to Rs 436.68 crore in Q4 March 2017 over Q4 March 2016.

Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.

Powered by Capital Market - Live News

Vivimed Labs spurts after unit completes USFDA inspection
Jun 07,2017

The announcement was made after market hours yesterday, 6 June 2017.

Meanwhile, the S&P BSE Sensex was up 129.40 points, or 0.41% at 31,319.96. The S&P BSE Small-Cap index was up 133.81 points, or 0.87% at 15,444.34.

On the BSE, 3.48 lakh shares were traded on the counter so far as against the average daily volume of 2.81 lakh shares in the past one quarter. The stock had hit a high of Rs 113.90 and a low of Rs 109.25 so far during the day. The stock had hit a record high of Rs 136.40 on 20 April 2017 and hit a 52-week low of Rs 68 on 9 August 2016.

The stock had underperformed the market over the past one month till 6 June 2017, declining 3.67% compared with the Sensexs 4.46% rise. The scrip had also underperformed the market over the past one quarter advancing 2.59% as against the Sensexs 7.38% rise. The scrip had, however, outperformed the market over the past one year advancing 32.97% as against the Sensexs 16.48% rise.

The small-cap company has equity capital of Rs 16.40 crore. Face value per share is Rs 2.

Vivimed Labs said that its active pharmaceutical ingredient (API) manufacturing facility located in Sant Celoni, Spain was recently inspected by the US Food and Drug Administration (USFDA) in compliance with their requirements. At the end of the successful inspection, we have been informed by the investigator that zero 483 observations were issued. This was a routine inspection by the USFDA, the company said.

Vivimed Labs consolidated net profit spurted 810% to Rs 114.75 crore on 25.8% increase in net sales to Rs 436.68 crore in Q4 March 2017 over Q4 March 2016.

Vivimed Labs is a niche specialty chemicals and pharmaceuticals company.

Powered by Capital Market - Live News

Sical Logistics advances after new order win
Jun 07,2017

The announcement was made after market hours yesterday, 6 June 2017.

Meanwhile, the S&P BSE Sensex was up 132.75 points or 0.43% at 31,323.31. The S&P BSE Small-Cap index was up 135.04 points, or 0.88% at 15,445.57.

On BSE, so far 13,000 shares were traded in the counter as against average daily volume of 10,765 shares in the past one quarter. The stock hit a high of Rs 265.20 and a low of Rs 254 so far during the day. The stock had hit a 52-week high of Rs 285 on 11 May 2017. The stock had hit a 52-week low of Rs 142 on 10 August 2016.

The small-cap company has equity capital of Rs 55.60 crore. Face value per share is Rs 10.

Sical Logistics said that the company has been awarded with a Letter of Acceptance by Mahanandi Coal Fields at a contracted value of Rs 289 crore. The contract is for extraction of coal / coal measure strata by deploying surface miners on hiring basis, mechanical transfer of the same by pay loaders into tipping trucks and transportation from surface miner face to different destinations at Bharatpur for an extraction quantity of 24368779 Cu.M. over a period of 1,095 days (three years).

On consolidated basis, Sical Logistics net profit increased 55.51% to Rs 14.12 crore on 16.81% growth in total income to Rs 263.48 crore in Q4 March 2017 over Q4 March 2016.

Sical Logistics is integrated logistics solutions provider providing end to end logistics solutions.

Powered by Capital Market - Live News

Unichem Labs gains after receiving inspection report from USFDA
Jun 07,2017

The announcement was made during trading hours today, 7 June 2017.

Meanwhile, the S&P BSE Sensex was up 146.95 points, or 0.47% to 31,337.51.

On the BSE, 13,000 shares were traded in the counter so far, compared with average daily volumes of 35,519 shares in the past one quarter. The stock had hit a high of Rs 264.10 and a low of Rs 247 so far during the day. The stock hit a 52-week high of Rs 319.90 on 20 October 2016. The stock hit a 52-week low of Rs 239.05 on 30 May 2017.

The stock had underperformed the market over the past one month till 6 June 2017, falling 7.30% compared with 4.23% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 6.34% as against Sensexs 7.92% rise. The scrip had also underperformed the market in past one year, falling 4.32% as against Sensexs 15.48% rise.

The small-cap company has equity capital of Rs 18.18 crore. Face value per share is Rs 2.

Unichem Laboratories said that its formulations manufacturing facility at Ghaziabad has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). This receipt indicates the successful closure of the inspection and the queries raised during the audit (Form 483). The inspection has now been closed by the USFDA. The inspection was carried out between 24 Feb 2017 to 3 March 2017.

Net profit of Unichem Laboratories rose 13.62% to Rs 31.46 crore on 12.83% rise in net sales to Rs 339.78 crore in Q4 March 2017 over Q4 March 2016.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

Powered by Capital Market - Live News

Adani Power gains after board OKs spinning out Mundra unit
Jun 07,2017

Meanwhile, the S&P BSE Sensex was up 78.89 points, or 0.25% to 31,269.45.

On the BSE, 2.69 lakh shares were traded in the counter so far, compared with average daily volumes of 20.92 lakh shares in the past one quarter. The stock had hit a high of Rs 28 and a low of Rs 27.55 so far during the day.

The stock hit a 52-week high of Rs 46.30 on 11 April 2017. The stock hit a 52-week low of Rs 23.35 on 9 November 2016.

The stock had underperformed the market over the past one month till 6 June 2017, falling 11.81% compared with 4.23% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 29.22% as against Sensexs 7.92% rise. The scrip had also underperformed the market in past one year, falling 9.02% as against Sensexs 15.48% rise.

The large-cap company has equity capital of Rs 3856.94 crore. Face value per share is Rs 10.

Adani Power announced after market hours yesterday, 6 June 2017, that its board approved a proposal to hive off its flagship Mundra power generating business undertaking, generating 4620 megawatts (MW) of power, to its subsidiary company, namely, Adani Power (Mundra). The transaction will put Mundra undertaking at par with the other operating subsidiaries of the company, with specific strategic focus as well as specific financial arrangements.

On a consolidated basis, Adani Power reported net loss of Rs 4960.53 crore in Q4 March 2017 as against net profit of Rs 1012.19 crore in Q4 March 2016. Net sales declined 16.91% to Rs 6352.23 crore in Q4 March 2017 over Q4 March 2016.

Adani Power is the largest private power producer in India with an installed capacity of 10,480 MW.

Powered by Capital Market - Live News

Adani Power rises after board OKs spinning out Mundra unit
Jun 07,2017

Meanwhile, the S&P BSE Sensex was up 78.89 points, or 0.25% to 31,269.45.

On the BSE, 2.69 lakh shares were traded in the counter so far, compared with average daily volumes of 20.92 lakh shares in the past one quarter. The stock had hit a high of Rs 28 and a low of Rs 27.55 so far during the day.

The stock hit a 52-week high of Rs 46.30 on 11 April 2017. The stock hit a 52-week low of Rs 23.35 on 9 November 2016.

The stock had underperformed the market over the past one month till 6 June 2017, falling 11.81% compared with 4.23% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 29.22% as against Sensexs 7.92% rise. The scrip had also underperformed the market in past one year, falling 9.02% as against Sensexs 15.48% rise.

The large-cap company has equity capital of Rs 3856.94 crore. Face value per share is Rs 10.

Adani Power announced after market hours yesterday, 6 June 2017, that its board approved a proposal to hive off its flagship Mundra power generating business undertaking, generating 4620 megawatts (MW) of power, to its subsidiary company, namely, Adani Power (Mundra). The transaction will put Mundra undertaking at par with the other operating subsidiaries of the company, with specific strategic focus as well as specific financial arrangements.

On a consolidated basis, Adani Power reported net loss of Rs 4960.53 crore in Q4 March 2017 as against net profit of Rs 1012.19 crore in Q4 March 2016. Net sales declined 16.91% to Rs 6352.23 crore in Q4 March 2017 over Q4 March 2016.

Adani Power is the largest private power producer in India with an installed capacity of 10,480 MW.

Powered by Capital Market - Live News

Dilip Buildcon builds gains after bulk deal
Jun 06,2017

Meanwhile, the S&P BSE Sensex was down 118.93 points or 0.38% at 31,190.56. The S&P BSE Mid-Cap index was down 91.67 points or 0.62% at 14,732.39.

Bulk deal boosted volume on the scrip. On the BSE, 8.03 lakh shares were traded on the counter as against the average daily volumes of 47,083 shares in the past one quarter. The stock had hit a high of Rs 457.45 and a low of Rs 427.50 in intraday trade. The stock had hit a record high of Rs 529.45 on 18 May 2017. The stock had hit a record low of Rs 178.60 on 9 November 2016.

The stock had underperformed the market over the past one month till 5 June 2017, falling 2.77% compared with 4.86% rise in the Sensex. The scrip, however, outperformed the market in past one quarter, gaining 35.01% as against Sensexs 7.97% rise.

The mid-cap company has equity capital of Rs 136.77 crore. Face value per share is Rs 10.

Dilip Buildcons net profit jumped 222.5% to Rs 195.77 crore on 28.8% growth in net sales to Rs 1732.30 crore in Q4 March 2017 over Q4 March 2016.

Dilip Buildcon is a road-focused engineering procurement construction (EPC) contractor. The company develops infrastructure across the country in diverse areas such as roads & bridges, water sanitation & sewage, irrigation, industrial, commercial & residential buildings.

Powered by Capital Market - Live News

HDIL drops in volatile trade after foreign fund buying
Jun 06,2017

Meanwhile, the S&P BSE Sensex was down 129.05 points or 0.41% at 31,180.44. The S&P BSE Mid-Cap index was down 92.05 points or 0.62% at 14,732.01.

On the BSE, 29.81 lakh shares were traded on the counter so far as against the average daily volumes of 22.31 lakh shares in the past one quarter. The stock saw high intraday volatility. The stock had hit a high of Rs 96.15 and a low of Rs 91.55 so far during the day. The stock had hit a 52-week high of Rs 108.75 on 12 July 2016 and a 52-week low of Rs 52.25 on 27 December 2016.

The mid-cap company has equity capital of Rs 434 crore. Face value per share is Rs 10.

Shares of Housing Development & Infrastructure (HDIL) had gained 4.23% to settle at Rs 93.60 yesterday, 5 May 2017. Foreign fund Societe Generale bought 25.32 lakh shares of HDIL at Rs 92.04 per share in a bulk deal on NSE yesterday, 5 June 2017.

HDILs consolidated net profit rose 28% to Rs 60.88 crore on 61.62% decline in net sales to Rs 129.51 crore in Q4 March 2017 over Q4 March 2016.

HDIL is a real estate development company, with significant operations in the Mumbai Metropolitan Region.

Powered by Capital Market - Live News

Volumes jump at ITD Cementation India counter
Jun 06,2017

ITD Cementation India clocked volume of 16.28 lakh shares by 15:03 IST on BSE, a 79.99-times surge over two-week average daily volume of 20,000 shares. The stock lost 2.82% to Rs 172.30.

Steel Strips Wheels notched up volume of 1.57 lakh shares, a 63.92-fold surge over two-week average daily volume of 2,000 shares. The stock fell 0.9% to Rs 893.95.

Page Industries saw volume of 26,000 shares, a 40.29-fold surge over two-week average daily volume of 655 shares. The stock rose 3.21% to Rs 1,4950.05.

Dilip Buildcon clocked volume of 7.90 lakh shares, a 22.60-fold surge over two-week average daily volume of 35,000 shares. The stock rose 0.66% to Rs 432.80

TVS Motor Company saw volume of 15.55 lakh shares, a 17.39-fold rise over two-week average daily volume of 89,000 shares. The stock fell 0.77% to Rs 538.

Powered by Capital Market - Live News

Hotel Leelaventure tumbles on profit booking
Jun 06,2017

Meanwhile, the S&P BSE Sensex was down 132.63 points, or 0.42% to 31,176.86.

On the BSE, 1.22 lakh shares were traded in the counter so far, compared with average daily volumes of 2.86 lakh shares in the past one quarter. The stock had hit a high of Rs 25.15 and a low of Rs 24.20 so far during the day. The stock hit a 52-week high of Rs 27.25 on 10 May 2017. The stock hit a 52-week low of Rs 15 on 25 November 2016.

The stock had outperformed the market over the past one month till 5 June 2017, rising 25.75% compared with 4.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 49.70% as against Sensexs 7.97% rise. The scrip had also outperformed the market in past one year, rising 41.69% as against Sensexs 16.92% rise.

The small-cap company has equity capital of Rs 93.32 crore. Face value per share is Rs 2.

Shares of Hotel Leelaventure rose 11.78% in two trading sessions to settle at Rs 25.15 yesterday, 5 June 2017, from its close of Rs 22.50 on 1 June 2017.

The recent rally in Hotel Leelaventure was triggered by the company confirming that it is in talks to sell the Leela Palace Chennai. The company issued clarification during market hours on Friday, 2 June 2017. Shares of Hotel Leelaventure rose 2.67% to settle at Rs 23.10 on that day.

Hotel Leelaventure added that, however, no binding agreement has been signed with any party as on date. The company issued the clarification after media reports indicated that Marigold Capital and Investments is likely to buy Leela Groups 326-room hotel in Chennai.

Marigold Capital and Investment is an American private equity fund and is looking to buy the hotel for around Rs 700 crore, reports said. Marigold Capital and Investments specialises in acquiring debt-ridden hotels and commercial real estate properties and turning them into profitable businesses.

Hotel Leelaventure reported net profit of Rs 13.42 in Q4 March 2017 compared with net loss of Rs 228.87 crore in Q4 March 2016. Net sales rose 2.3% to Rs 198.35 crore in Q4 March 2017 over Q4 March 2016.

Hotel Leelaventure is a leading Indian luxury hospitality group founded in 1986.

Powered by Capital Market - Live News

Sintex Industries recovers on bargain hunting
Jun 06,2017

Meanwhile, the S&P BSE Sensex was down 116.82 points, or 0.37% at 31,192.67. The S&P BSE Small-Cap index was down 117.62 points, or 0.76% at 15,292.33.

High volumes were witnessed on the counter. On the BSE, 49.31 lakh shares were traded on the counter so far as against the average daily volumes of 22.93 lakh shares in the past one quarter. The stock had hit a high of Rs 25.90 and a low of Rs 23.50 so far during the day. The stock had hit a 52-week high of Rs 34.50 on 25 May 2017 and a 52-week low of Rs 12.04 on 12 August 2016.

The stock had outperformed the market over the past one month till 5 June 2017, gaining 26.96% compared with the Sensexs 4.86% rise. The scrip had also outperformed the market over the past one quarter advancing 45.29% as against the Sensexs 8.59% rise. The scrip had also outperformed the market over the past one year advancing 87.02% as against the Sensexs 16.64% rise.

The small-cap company has equity capital of Rs 55.49 crore. Face value per share is Rs 1.

Shares of Sintex Industries had declined 19.5% in the preceding six trading sessions to settle at Rs 24.35 yesterday, 5 June 2017, from its closing of Rs 30.25 on 26 May 2017.

Sintex Industries consolidated net profit fell 78.7% to Rs 49.54 crore on 132.7% increase in net sales to Rs 661.40 crore in Q4 March 2017 over Q4 March 2016.

Sintex Industries is engaged in spinning, weaving and finishing of textiles.

Powered by Capital Market - Live News

Bharat Forge slips after decline in North America Class 8 truck orders
Jun 06,2017

Meanwhile, the S&P BSE Sensex was down 116.91 points, or 0.37% to 31,192.58.

On the BSE, 30,000 shares were traded in the counter so far, compared with average daily volumes of 98,466 shares in the past one quarter. The stock had hit a high of Rs 1,181.70 and a low of Rs 1,156.50 so far during the day. The stock hit a 52-week high of Rs 1,215 on 2 June 2017. The stock hit a 52-week low of Rs 686.80 on 24 June 2016.

The stock had outperformed the market over the past one month till 5 June 2017, rising 7.97% compared with 4.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 13.15% as against Sensexs 7.97% rise. The scrip had also outperformed the market in past one year, rising 60.11% as against Sensexs 16.92% rise.

The large-cap company has equity capital of Rs 46.56 crore. Face value per share is Rs 2.

As per FTR release, preliminary North America Class 8 truck orders plunged 31% to 16,300 units in May 2017 over April 2017. May orders, however, were still higher by 29% compared with May 2016.

About 30% of Bharat Forges revenue reportedly comes from North America truck market.

Net profit of Bharat Forge rose 25.32% to Rs 207.50 crore on 11.31% rise in net sales to Rs 1125.66 crore in Q4 March 2017 over Q4 March 2016.

Pune based Bharat Forge is a technology driven global leader in metal forming having transcontinental presence across ten manufacturing locations, serving several sectors including automotive, power, oil and gas, construction & mining , rail, marine and aerospace.

Powered by Capital Market - Live News